微信在线咨询
| 产品编号 | 产品名称 | 产品包装 | 产品价格 |
| SM4144-10mM | 盐酸小檗碱(98%, HPLC) | 10mM×0.2ml | 76.00元 |
| SM4144-25mg | 盐酸小檗碱(98%, HPLC) | 25mg | 108.00元 |
| SM4144-100mg | 盐酸小檗碱(98%, HPLC) | 100mg | 367.00元 |
| 中文名 | 盐酸小檗碱 |
| 英文名 | Berberine chloride |
| 中文别名 | 盐酸黄连素 |
| 英文别名 | Berberine hydrochloride; Natural Yellow 18 chloride |
| 来源 | 黄连Coptis chinensis Franch.；黄皮树Phellodendron chinense Schneid. |
| 化合物类型 | 生物碱(Alkaloids)>异喹啉生物碱>小檗碱型生物碱 |
| 化学式 | C20H18ClNO4 |
| 分子量 | 371.81 |
| CAS号 | 633-65-8 |
| 纯度 | 98%, HPLC |
| 溶剂/溶解度 |
DMSO: 12.5 mg/ml (33.62 mM) Water: < 0.1 mg/ml (insoluble) |
| 溶液配制 | 5mg加入1.34ml DMSO，或者每3.71mg加入1ml DMSO，配制成10mM溶液。 |
| 产品描述 | Berberine chloride is an alkaloid isolated from the Chinese herbal medicine Huanglian, as an antibiotic. Berberine chloride induces reactive oxygen species (ROS) generation and inhibits DNA topoisomerase. Antineoplastic properties. | ||||
| 信号通路 | - | ||||
| 靶点 | ROS | DNA topoisomerase | - | - | - |
| IC50 | - | - | - | - | - |
| 体外研究 | Berberine (1.25-160 μM; 72 hours) has potential inhibitory effects on the proliferation of four colorectal carcinoma cell lines LoVo, HCT116, SW480, and HT-29. Berberine (1.25-160 μM; 24-72 hours) induces a time- and dose-dependent inhibition of LoVo cell growth. LoVo cells are exposure to Berberine (10-80 μM) for 24 h. Cell cycle analysis of 40 μM Berberine-treated LoVo cells by flow cytometry shows accumulation of cells in the G2/M phase. Berberine (10-80 μM) suppresses cyclin B1, cdc2 and cdc25c protein expression after 24 h, especially at the dose of 80.0 μM. | ||||
| 体内研究 | Berberine (10, 30, or 50 mg/kg/day; gastrointestinal gavage; for 10 consecutive days) inhibits the growth of human colorectal adenocarcinoma in vivo. Berberine at doses of 30 and 50 mg/kg/day taken by gastrointestinal gavage shows inhibitory rates of 33.1% and 45.3% on the human colorectal adenocarcinoma xenograft growth in nude mice. | ||||
| 临床实验 | NCT04479202: Berberine|COVID-19, Phase 4; NCT03708549: Schizophrenia|Metabolic Syndrome|Berberine| Metformin, Phase 4; NCT02808351: Diabetes Mellitus|Chronic Kidney Disease, Phase 4; NCT03609892: Gastric Ulcer|Chronic Gastritis|Gastric Cancer|Helicobacter Pylori Infection|Gastritis, Phase 4; NCT02296021: Gastritis|Peptic Ulcer|Dyspepsia, Phase 4; NCT02633930: Gastritis|Peptic Ulcer|Dyspepsia, Phase 4; NCT03029390: Prediabetes|Impaired Fasting Glucose|Impaired Glucose Tolerance, Phase 4; NCT03198572: Non-alcoholic Steatohepatitis, Phase 4; NCT03548155: Schizophrenia|Therapeutics, Phase 4; NCT02962245: Ulcerative Colitis, Phase 4; NCT03378934: Coronary Artery Disease|Percutaneous Coronary Intervention, Phase 4; | ||||
1.Cai Y, et al. J Nat Med. 2014,68(1):53-62.
包装清单：| 产品编号 | 产品名称 | 包装 |
| SM4144-10mM | 盐酸小檗碱(98%, HPLC) | 10mM×0.2ml |
| SM4144-25mg | 盐酸小檗碱(98%, HPLC) | 25mg |
| SM4144-100mg | 盐酸小檗碱(98%, HPLC) | 100mg |
| － | 说明书 | 1份 |
-20℃保存，至少一年有效。固体粉末4℃保存，至少一个月有效。如果溶于非DMSO溶剂，建议分装后-80℃保存，预计6个月内有效。
注意事项：本产品可能对人体有一定的毒害作用，请注意适当防护，以避免直接接触人体或吸入体内。
本产品仅限于专业人员的科学研究用，不得用于临床诊断或治疗，不得用于食品或药品，不得存放于普通住宅内。
为了您的安全和健康，请穿实验服并戴一次性手套操作。
微信在线咨询
